TAVT-45 Demonstrates Therapeutic Equivalence to Abiraterone Acetate Tablets in Metastatic Prostate Cancer

Article

Patients with metastatic prostate cancer and dysphagia or difficulty swallowing may benefit from TAVT-45 compared with abiraterone acetate tablets.

TAVT-45 granules for oral suspension (abiraterone acetate) yielded positive topline results and demonstrated therapeutic equivalence to abiraterone tablets (Zytiga) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), according to a press release from Tavanta Therapeutics on data from the phase 3 TAVT45C02 trial (NCT04887506).

The primary end point of the trial was reached, as TAVT-45 and abiraterone tablets yielded comparable serum testosterone levels at days 9 and 10 of treatment vs the tablets. Additionally, the key secondary end point of reducing prostate-specific antigen levels by 50% or more from baseline did not show a statistical difference between the treatment arms. Moreover, the safety profile of TAVT-45 was consistent with those reported when abiraterone tablets were used.

“It is encouraging to see a familiar efficacy and safety profile for TAVT-45, which is consistent with data established for abiraterone as a standard of care in the treatment of metastatic prostate cancer,” study investigator Kenneth M. Kernen, MD, a partner at the Michigan Institute of Urology, said in the press release. “The positive results from this clinical study further support and validate the use of TAVT-45 as a novel, oral, easy-to-drink formulation of abiraterone acetate.”

TAVT-45 is an alternative formulation of abiraterone acetate designed for the treatment of metastatic prostate cancer by producing an oral suspension when reconstituted with water or juice. The agent may benefit a population of patients who have dysphagia or difficulty swallowing tablets, potentially increasing the bioavailability of abiraterone and allowing a lower dose to be taken.

Investigators of the global, randomized, multi-center, open-label phase 3 TAVT45C02 trial evaluated the pharmacokinetics, efficacy, and safety of TAVT-45 and abiraterone tablets in combination with prednisone among patients with mCRPC or high-risk mCSPC.

Patients were randomly assigned to either receive 250 mg of TAVT-45 granules for oral suspension twice a day or 500 mg of abiraterone tablets once daily. Patients in both arms also received 5 mg of prednisone once per day if they had mCSPC or twice a day if they had mCRPC.

Patients 18 years and older with a pathologically confirmed diagnosis of adenocarcinoma of the prostate were eligible to enroll on the trial. Additional inclusion criteria included having received ongoing therapy with a gonadotropin releasing hormone agonist or antagonist, having an ECOG performance status of 0 to 2 at screening, normal organ function with acceptable laboratory values, and a life expectancy of at least 6 months at screening.

Patients who initiated bisphosphonate or denosumab therapy 4 weeks prior to beginning treatment were unable to enroll on the study. Patients were also unsuitable for enrollment if they had therapy with estrogen 4 weeks before the start of study treatment, known central nervous system metastases, a history of adrenal gland dysfunction, or a history of other malignancies within the 2 previous years.

“Approximately 20 to 30 percent of [patients with] cancer, including many patients with prostate cancer, have difficulty swallowing pills and capsules. We believe these patients may benefit from an alternate formulation like TAVT-45 that would allow them to take their much-needed medications in an easier-to-take formulation,” Andreas Maetzel, MD, PhD, chief medical officer at Tavanta Therapeutics, concluded.

Reference

Tavanta Therapeutics announces positive top-line results from pivotal phase 3 Trial of TAVT-45 for the treatment of metastatic prostate cancer. News release. Tavanta Therapeutics. January 5, 2023. Accessed January 9, 2023. bit.ly/3XmeZFL

Related Videos
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Related Content